Table 3.

Correlation of metabolic values of primary tumour below optimal cutoffs with treatment outcomes: patients treated with concurrent radiation therapy and systemic therapy (with and without Cetuximab)

	Radiation Therapy with concurrent systemic therapy including Cetuximab (n = 72)					Radiation Therapy with concurrent systemic therapy excluding Cetuximab (n = 57)
	Value	Number		2 year Kaplan-Meier	p value	Value	Number		2-year Kaplan-Meier	p value
SUVmax	≤ 4.25	30	DFS	82.20 %		≤ 4.25	24	DFS	81.70 %
	> 4.25	42		64.50 %	0.025	> 4.25	33		57.70 %	0.064
	≤ 4.25	30	LRFS	88.80 %		≤ 4.25	24	LRFS	85.60 %
	> 4.25	42		74.90 %	0.03	> 4.25	33		67.00 %	0.126
	≤ 4.25	30	OS	80.80 %		≤ 4.25	24	OS	81.10 %
	> 4.25	42		75.00 %	0.345	> 4.25	33		66.50 %	0.308
MTV	≤ 3.3	32	DFS	83.20 %		≤ 3.3	25	DFS	82.40 %
	> 3.3	40		62.30 %	0.018	> 3.3	32		56.00 %	0.072
	≤ 3.3	32	LRFS	89.80 %		≤ 3.3	25	LRFS	86.50 %
	> 3.3	40		68.50 %	0.022	> 3.3	32		65.20 %	0.132
	≤ 3.3	32	OS	78.30 %		≤ 3.3	25	OS	76.50 %
	> 3.3	40		73.00 %	0.512	> 3.3	32		69.90 %	0.68
TLG	≤ 9.4	31	DFS	85.90 %		≤ 9.4	24	DFS	85.90 %
	> 9.4	41		60.80 %	0.005	> 9.4	33		54.30 %	0.022
	≤ 9.4	31	LRFS	92.70 %		≤ 9.4	24	LRFS	90.20 %
	> 9.4	41		71.10 %	0.005	> 9.4	33		63.20 %	0.038
	≤ 9.4	31	OS	81.10 %		≤ 9.4	24	OS	80.20 %
	> 9.4	41		75.00 %	0.279	> 9.4	33		64.60 %	0.37

SUV_max = maximum standardised uptake value; MTV = metabolic tumour volume; TLG = total lesional glycolysis; DFS = disease-free survival; LRFS = loco-regional failure-free survival; OS = overall survival